Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation
暂无分享,去创建一个
[1] Uma Yasothan,et al. Brentuximab vedotin , 2022, Nature Reviews Drug Discovery.
[2] P. Timpson. Faculty Opinions recommendation of The topography of mutational processes in breast cancer genomes. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[3] M. Shipp,et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Blaser,et al. The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. , 2016, Journal of the National Cancer Institute.
[5] K. Harrington,et al. Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 , 2016 .
[6] M. L. Calle,et al. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.
[7] HaroldC. Smith,et al. The APOBEC Protein Family: United by Structure, Divergent in Function. , 2016, Trends in biochemical sciences.
[8] L. Pleyer,et al. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality? , 2016, International journal of molecular sciences.
[9] G. Freeman,et al. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma , 2016, Scientific Reports.
[10] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[11] James X. Sun,et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. , 2016 .
[12] J. Desai,et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). , 2016 .
[13] S. Mortimer,et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. , 2016 .
[14] R. Dummer,et al. The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. , 2016 .
[15] R. Bourgon,et al. PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). , 2016 .
[16] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[17] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[18] A. Jakubowiak,et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial , 2016, The Lancet.
[19] Haiyi Jiang,et al. Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] A. Sieuwerts,et al. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma , 2016, Clinical Cancer Research.
[21] A. Taddei,et al. The interplay between the microbiome and the adaptive immune response in cancer development , 2016, Therapeutic advances in gastroenterology.
[22] C. Flowers,et al. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. , 2016, Clinical colorectal cancer.
[23] Yan Cai,et al. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression , 2016, Tumor Biology.
[24] M. Guerreiro,et al. Trastuzumab in the Treatment of Breast Cancer , 2016, BioDrugs.
[25] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[26] Amanda R. Campbell,et al. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. , 2016, Cancer research.
[27] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[28] G. Lesinski,et al. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer , 2015, Clinical Cancer Research.
[29] T. Kipps,et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.
[30] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[31] J. Gartner,et al. Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.
[32] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[33] J. Gartner,et al. Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes , 2015, Journal of Immunotherapy for Cancer.
[34] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[35] I. Márquez-Rodas,et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. , 2015, Annals of translational medicine.
[36] Preet Paul Singh,et al. Immune checkpoints and immunotherapy for colorectal cancer , 2015, Gastroenterology report.
[37] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[38] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[39] Gad Getz,et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.
[40] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[41] I. Melero,et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.
[42] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[43] Carsten Denkert,et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.
[44] C. Swanton,et al. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.
[45] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[46] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Jedd D. Wolchok,et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.
[48] A. Ng,et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab , 2015, Oncoimmunology.
[49] A. Eggermont,et al. Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.
[50] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[51] P. Stephens,et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. , 2015, The oncologist.
[52] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.
[53] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[54] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[55] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[56] Carsten Denkert,et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] H. Kohrt,et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.
[58] Benjamin Haibe-Kains,et al. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation , 2015, Proceedings of the National Academy of Sciences.
[59] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[60] M. Vetizou,et al. Cancer and the gut microbiota: An unexpected link , 2015, Science Translational Medicine.
[61] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[62] Gordon Cook,et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.
[63] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[64] C. Craddock,et al. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia , 2014, Annals of Hematology.
[65] K. Kinzler,et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.
[66] J. Byrd,et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.
[67] S. Henderson,et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.
[68] B. Isermann,et al. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function , 2014, Haematologica.
[69] G. Trinchieri,et al. Gut microbiome and anticancer immune response: really hot Sh*t! , 2014, Cell Death and Differentiation.
[70] R. Greil,et al. APOBEC3 signature mutations in chronic lymphocytic leukemia , 2014, Leukemia.
[71] Antoni Ribas,et al. Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.
[72] R. Greil,et al. Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia , 2014, European journal of immunology.
[73] Ryan Emerson,et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.
[74] Chris P. Miller,et al. JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors , 2014, Cancer Immunology Research.
[75] Sung-Liang Yu,et al. Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity , 2014, International journal of cancer.
[76] F. Marincola,et al. Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.
[77] Eric Vivier,et al. The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.
[78] A. Rudensky,et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.
[79] J. Wolchok,et al. Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor , 2013, Cancer Immunology Research.
[80] Jeffrey A Jones,et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.
[81] N. A. Temiz,et al. Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.
[82] Steven A. Roberts,et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.
[83] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[84] M. Nussenzweig,et al. Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. , 2013, Annual review of pathology.
[85] S. Fagarasan,et al. Impaired selection of IgA and intestinal dysbiosis associated with PD-1-deficiency , 2013, Gut microbes.
[86] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[87] H. Tjalsma,et al. Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer , 2012, Biological reviews of the Cambridge Philosophical Society.
[88] J. Moorman,et al. Tim-3 Pathway Controls Regulatory and Effector T Cell Balance during Hepatitis C Virus Infection , 2012, The Journal of Immunology.
[89] Bas E Dutilh,et al. A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects , 2012, Nature Reviews Microbiology.
[90] S. Tannenbaum,et al. Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer , 2012, Proceedings of the National Academy of Sciences.
[91] D. Maloney. Anti-CD20 antibody therapy for B-cell lymphomas. , 2012, The New England journal of medicine.
[92] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[93] Peter Vogel,et al. Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .
[94] U. Gophna. The Guts of Dietary Habits , 2011, Science.
[95] J. Gordon,et al. Human nutrition, the gut microbiome and the immune system , 2011, Nature.
[96] F. Ghiringhelli,et al. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.
[97] E John Wherry,et al. T cell exhaustion , 2011 .
[98] P. Bork,et al. Enterotypes of the human gut microbiome , 2011, Nature.
[99] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[100] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.
[101] J. Kirkwood,et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.
[102] M. Kadin,et al. Targeted therapies: Denileukin diftitox—a step towards a 'magic bullet' for CTCL , 2010, Nature Reviews Clinical Oncology.
[103] R. Lorenz,et al. Role of Postnatal Acquisition of the Intestinal Microbiome in the Early Development of Immune Function , 2010, Journal of pediatric gastroenterology and nutrition.
[104] Loise M. Francisco,et al. The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.
[105] Cynthia L Sears,et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.
[106] S. Mazmanian,et al. The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.
[107] M. Croft. The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.
[108] M. Ligtenberg,et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.
[109] A. Stringer,et al. Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats , 2008, Cancer biology & therapy.
[110] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[111] A. Sharpe,et al. Induction of autoimmune disease in CTLA-4−/− mice depends on a specific CD28 motif that is required for in vivo costimulation , 2007, Proceedings of the National Academy of Sciences.
[112] Carmen Buchrieser,et al. Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells , 2006, Science.
[113] J. Nicoli,et al. Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions , 2005, Parasitology.
[114] J. Nicoli,et al. Influence of normal microbiota on some aspects of the immune response during experimental infection with Trypanosoma cruzi in mice. , 2004, Journal of medical microbiology.
[115] R. Greil,et al. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools , 2003, Journal of leukocyte biology.
[116] T. Honjo,et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.
[117] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] D. C. Cara,et al. Monoassociation with Lactobacillus acidophilus UFV-H2b20 stimulates the immune defense mechanisms of germfree mice. , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[119] R. Greil,et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. , 1998, Blood.
[120] R. Greil,et al. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.
[121] R. Greil,et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. , 1997, Blood.
[122] M Nomura,et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.
[123] A. Nagler,et al. Role of interleukin-2 in human hematological malignancies , 1995, Medical oncology.
[124] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[125] J. Cawley,et al. The current status of interferonα in haemic malignancy , 1990 .
[126] W. Coley,et al. Contribution To The Knowledge Of Sarcoma , 1891 .
[127] E. Levanon,et al. DNA Editing by APOBECs: A Genomic Preserver and Transformer. , 2016, Trends in genetics : TIG.
[128] ADC Shows Effectiveness in SCLC. , 2015, Cancer discovery.
[129] S. Mazmanian,et al. The gut microbiome shapes intestinal immune responses during health and disease , 2014 .
[130] R. Greil,et al. Tuning the rheostat of the myelopoietic system via Fas and TRAIL. , 2003, Critical reviews in immunology.
[131] A. Eggermont,et al. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. , 1997, Journal of immunotherapy.
[132] J. Cawley,et al. The current status of interferon alpha in haemic malignancy. , 1990, Blood reviews.
[133] K. Calman,et al. Immunological Aspects of Cancer Chemotherapy , 1980 .